VIYASH SCIENTIFIC LIMITED

Viyash Scientific Limited reported strong financial results for Q1 FY’27, with revenue from operations reaching Rs. 946 crores, a 20% year-on-year increase. EBITDA grew by 59% to Rs. 205 crores, resulting in an EBITDA margin of 21.6%, up 530 basis points from the previous year. Profit after tax more than doubled to Rs. 79 crores. The company highlighted improvements in its balance sheet, with net debt reduced to Rs. 86 crores and a net debt to EBITDA ratio of 0.1x. Management noted strong growth in both the Animal Health and Human Formulation segments, with a focus on new product launches and geographic expansion. The acquisition of Bio For Life in Italy was discussed as a strategic move to enhance the company's presence in the companion animal market. Overall, management expressed confidence in maintaining double-digit revenue growth and improving profitability going forward.

Management emphasized strong financial performance and growth opportunities.